The world’s first Phase III trial is the result of a cooperation partnership between Abu Dhabi based G42 Healthcare, currently at the forefront of the battle against COVID-19 in the UAE, and Sinopharm CNBG, the world’s sixth largest vaccine manufacturer, ranked 169th on the Fortune Global 500 list of 2018.